Paris polyphylla var. chinensis

as an important source of Paridis Rhizoma in Chinese Pharmacopoeia

has many pharmacological efficacies

such as clearing heat and toxic matter

relieving swelling and pain

cooling the liver and relieving convulsion

and been clinically used for anti-tumor

antibiosis

hemostasis

analgesia and so on. P. polyphylla var. chinensis

as a perennial plant

has a low reproductive rate and long growth period

with seven years from seed germination to medical application. Recently

its wild plant resources became rare because of the excessive excavation

which cannot meet the need of the market

caused a high market price

and even posed a serious threat to the survival and sustainable use of its resources. To solve this problem

developing artificial breeding technology and breeding the cultivated species are the best way to protect the wild plant resources and meet the clinical demands. Literature related to the breeding technology of P. polyphylla var. chinensis were retrieved and summarized to make a review about seed collection and seedling

so as to provide the theoretical guidance for the artificial breeding. Meanwhile

the breeding quality was discussed based on the correlative chemical composition during the growth of the seedlings. The breeding technology of P. polyphylla var. chinensis is the first important step to breed good-quality varieties

while the detection for the subsequent quality is significant as well. In this article

the quality evaluation system was established for wild and bred varieties in a multi-disciplinary and multi-angle manner

in order to guarantee the quality of Chinese medicinal materials

and provide a reference for further exploitation and utilization of P. polyphylla var. chinensis.